We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+131.02%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$143M
AUM Growth
+$40.4M
Cap. Flow
+$11.7M
Cap. Flow %
8.18%
Top 10 Hldgs %
81.78%
Holding
32
New
7
Increased
10
Reduced
6
Closed
9

Top Buys

Rank Stock Value
1
AFMD
Affimed
AFMD
+$10.5M
2
ADMS
Adamas Pharmaceuticals
ADMS
+$7.13M
3
AMRN
Amarin Corp
AMRN
+$5.92M
4
EOLS icon
Evolus
EOLS
+$5.57M
5
APVO icon
Aptevo Therapeutics
APVO
+$4.98M

Top Sells

Rank Stock Value
1
BDSI
BioDelivery Sciences International, Inc.
BDSI
+$10.9M
2
ENTA icon
Enanta Pharmaceuticals
ENTA
+$7.8M
3
LGND icon
Ligand Pharmaceuticals
LGND
+$2.98M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$2.95M
5
ALIM
Alimera Sciences
ALIM
+$1.55M

Sector Composition

Rank Sector Weight
1 Healthcare 92.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KALV
26
DELISTED
KalVista Pharmaceuticals
KALV
– –
-33,033
Closed -$383K
LGND icon
27
Ligand Pharmaceuticals
LGND
$5.96B
– –
-48,034
Closed -$2.98M
TVTX icon
28
Travere Therapeutics
TVTX
$5.27B
– –
-29,675
Closed -$344K
ALIM
29
DELISTED
Alimera Sciences
ALIM
– –
-182,694
Closed -$1.55M
CORV
30
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
– –
-509,356
Closed -$1.02M
BDSI
31
DELISTED
BioDelivery Sciences International, Inc.
BDSI
– –
-2,595,855
Closed -$10.9M
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, Stonepine Capital Management held 32 positions worth $143M, up 39% from $103M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Stonepine Capital Management deployed $11.7M of net new capital in Q4 2019, opening 7 new positions and adding to 10 existing holdings. Its largest new stake was Evolus: 394,890 shares worth $4.81M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 96% a quarter earlier.

On the sell side, the largest reduction was IVERIC bio, Inc. Common Stock, an estimated $2.95M trimmed.

  • Stonepine Capital Management's largest Q4 2019 buy was Evolus: 394,890 shares worth $4.81M.
  • Stonepine Capital Management added most to Affimed in Q4 2019, an estimated $10.5M increase.
  • Stonepine Capital Management's biggest Q4 2019 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $2.95M.
  • Stonepine Capital Management fully exited BioDelivery Sciences International, Inc. in Q4 2019, selling an estimated $10.9M.
  • Stonepine Capital Management's ten largest holdings make up 82% of its $143M portfolio in Q4 2019.
  • Stonepine Capital Management opened 7 new positions and closed 9 in Q4 2019.
  • Stonepine Capital Management's portfolio value rose 39% quarter-over-quarter to $143M.

Based on Stonepine Capital Management's 13F filing for Q4 2019, filed 13 Feb 2020.